These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

411 related articles for article (PubMed ID: 24944485)

  • 1. Helicobacter pylori eradication with moxifloxacin-containing therapy following failed first-line therapies in South Korea.
    Kang KK; Lee DH; Oh DH; Yoon H; Shin CM; Park YS; Kim N; Jung HC
    World J Gastroenterol; 2014 Jun; 20(22):6932-8. PubMed ID: 24944485
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of 14-d vs 7-d moxifloxacin-based triple regimens for second-line Helicobacter pylori eradication.
    Hwang JJ; Lee DH; Lee AR; Yoon H; Shin CM; Park YS; Kim N
    World J Gastroenterol; 2015 May; 21(18):5568-74. PubMed ID: 25987781
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Moxifloxacin-containing triple therapy after non-bismuth quadruple therapy failure for Helicobacter pylori infection.
    Lim JH; Lee DH; Lee ST; Kim N; Park YS; Shin CM; Song IS
    World J Gastroenterol; 2015 Dec; 21(46):13124-31. PubMed ID: 26673999
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The Efficacy of Bismuth-containing Quadruple Therapy after Moxifloxacin-based Sequential Therapy Failure in Helicobacter pylori Eradication].
    Kwon S; Lee DH; Kang JB; Kim N; Park YS; Shin CM; Yoon H; Choi YJ
    Korean J Gastroenterol; 2018 Apr; 71(4):196-203. PubMed ID: 29684968
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The efficacy of moxifloxacin-containing triple therapy after standard triple, sequential, or concomitant therapy failure for Helicobacter pylori eradication in Korea.
    Chung KH; Lee DH; Jin E; Cho Y; Seo JY; Kim N; Jeong SH; Kim JW; Hwang JH; Shin CM
    Gut Liver; 2014 Nov; 8(6):605-11. PubMed ID: 25368747
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The Efficacy of Moxifloxacin-containing Triple Therapy after Hybrid Therapy Failure in
    Kwon S; Lee DH; Kang JB; Kim N; Park YS; Shin CM; Yoon H; Choi YJ
    Korean J Gastroenterol; 2017 Aug; 70(2):72-80. PubMed ID: 28830132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of moxifloxacin-based sequential therapy for first-line eradication of Helicobacter pylori infection in gastrointestinal disease.
    Hwang JJ; Lee DH; Lee AR; Yoon H; Shin CM; Park YS; Kim N
    World J Gastroenterol; 2015 Apr; 21(16):5032-8. PubMed ID: 25945019
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of moxifloxacin-based sequential and hybrid therapy for first-line Helicobacter pylori eradication.
    Hwang JJ; Lee DH; Yoon H; Shin CM; Park YS; Kim N
    World J Gastroenterol; 2015 Sep; 21(35):10234-41. PubMed ID: 26401089
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Two-week, high-dose proton pump inhibitor, moxifloxacin triple Helicobacter pylori therapy after failure of standard triple or non-bismuth quadruple treatments.
    Gisbert JP; Romano M; Molina-Infante J; Lucendo AJ; Medina E; Modolell I; Rodríguez-Tellez M; Gomez B; Barrio J; Perona M; Ortuño J; Ariño I; Domínguez-Muñoz JE; Perez-Aisa Á; Bermejo F; Domínguez JL; Almela P; Gomez-Camarero J; Millastre J; Martin-Noguerol E; Gravina AG; Martorano M; Miranda A; Federico A; Fernandez-Bermejo M; Angueira T; Ferrer-Barcelo L; Fernández N; Marín AC; McNicholl AG
    Dig Liver Dis; 2015 Feb; 47(2):108-13. PubMed ID: 25454706
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fourteen- vs seven-day bismuth-based quadruple therapy for second-line Helicobacter pylori eradication.
    Hwang JJ; Lee DH; Lee AR; Yoon H; Shin CM; Park YS; Kim N
    World J Gastroenterol; 2015 Jul; 21(26):8132-9. PubMed ID: 26185386
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of 7-Day and 14-Day Bismuth-Containing Quadruple Therapy and 7-Day and 14-Day Moxifloxacin-Based Triple Therapy as Second-Line Eradication for Helicobacter pylori Infection.
    Lee ST; Lee DH; Lim JH; Kim N; Park YS; Shin CM; Jo HJ; Song IS
    Gut Liver; 2015 Jul; 9(4):478-85. PubMed ID: 25071068
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of 7-day Bismuth Quadruple Therapy versus 14-day Moxifloxacin Triple Therapy for Second-line
    Kim SE; Roh JH; Park MI; Park SJ; Moon W; Kim JH; Jung K; Heo JJ
    Korean J Gastroenterol; 2019 Jan; 73(1):26-34. PubMed ID: 30690955
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of multistrain probiotic-containing yogurt on second-line triple therapy for Helicobacter pylori infection.
    Yoon H; Kim N; Kim JY; Park SY; Park JH; Jung HC; Song IS
    J Gastroenterol Hepatol; 2011 Jan; 26(1):44-8. PubMed ID: 21175792
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Concomitant therapy achieved the best eradication rate for Helicobacter pylori among various treatment strategies.
    Lee HJ; Kim JI; Lee JS; Jun EJ; Oh JH; Cheung DY; Chung WC; Kim BW; Kim SS
    World J Gastroenterol; 2015 Jan; 21(1):351-9. PubMed ID: 25574111
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of standard triple therapy, sequential therapy and moxifloxacin-based triple therapy for Helicobacter pylori infection: Patients' compliance and bacterial eradication rates.
    Rakici H; Akdoğan RA; Bedir R; Copur A; Yilmaz A
    J Dig Dis; 2014 Sep; 15(9):508-13. PubMed ID: 24980811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment options for Helicobacter pylori infection when proton pump inhibitor-based triple therapy fails in clinical practice.
    Lee JM; Breslin NP; Hyde DK; Buckley MJ; O'Morain CA
    Aliment Pharmacol Ther; 1999 Apr; 13(4):489-96. PubMed ID: 10215733
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Second-line treatment for Helicobacter pylori infection based on moxifloxacin triple therapy: a randomized controlled trial.
    Bago J; Pevec B; Tomić M; Marusić M; Bakula V; Bago P
    Wien Klin Wochenschr; 2009; 121(1-2):47-52. PubMed ID: 19263014
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trends in Helicobacter pylori eradication rates by first-line triple therapy and related factors in eradication therapy.
    Kim SE; Park MI; Park SJ; Moon W; Choi YJ; Cheon JH; Kwon HJ; Ku KH; Yoo CH; Kim JH; Lee GW; Song SE
    Korean J Intern Med; 2015 Nov; 30(6):801-7. PubMed ID: 26552455
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bismuth-based quadruple therapy modified with moxifloxacin for Helicobacter pylori eradication.
    Marušić M; Dominković L; Majstorović Barać K; Gulić S; Bago J; Pezerović D
    Minerva Gastroenterol Dietol; 2017 Jun; 63(2):80-84. PubMed ID: 27973462
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Second-line bismuth-containing quadruple therapy for
    Kim SE; Park MI; Park SJ; Moon W; Kim JH; Jung K; Kim HK; Lee YD
    World J Gastroenterol; 2017 Feb; 23(6):1059-1066. PubMed ID: 28246480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.